Kymriah
Kymriah is a medicine authorised by Swissmedic under authorisation number 66778. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Transplant: gene therapy product and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 18 October 2018 and the authorisation is valid without a time limit. ATC code L01XL04 places the medicine in the group Antineoplastic agents.
| Authorisation number | 66778 |
|---|---|
| Name | Kymriah |
| Full name | Kymriah, Zellsuspension zur Infusion |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Transplant: gene therapy product |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01XL04 |
| First authorisation | 18 October 2018 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Kymriah, Zellsuspension zur Infusion | A | 18 October 2018 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1–3 | Beutel | L01XL04 | 07.16.4. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Kymriah authorised in Switzerland?
Yes. Kymriah is authorised by Swissmedic under authorisation number 66778, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Kymriah have?
Kymriah is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Kymriah?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.